Xu L, Ye J M, Zhu S N, Zhao J Y, Xin L, Cheng Y J, Liu Q, Zhang H, Zhang S, Duan X N, Liu Y H
The Breast Disease Center of Peking University First Hospital, Beijing 100034, China.
Zhonghua Yi Xue Za Zhi. 2018 Mar 27;98(12):907-911. doi: 10.3760/cma.j.issn.0376-2491.2018.12.006.
To analyze docetaxel (T) and carboplatin (C) combined with trastuzumab (H) -TCH regimen as neoadjuvant systemic therapy in early breast cancer patients with human epidermal growth factor receptor 2 (HER-2) positive. From January 2008 to December 2014, the data of patients diagnosed as early breast cancer in Breast Disease Center of Peking University First Hospital were retrospective reviewed. The data of patients with HER-2 positive conducted TCH neoadjuvant therapy and surgery, and with the complete clinicopathological information were analyzed. A total of 77 cases were enrolled in this study. We defined G2+ G3+ G4+ G5 as responsive group according to Miller-Payne grading system, the responsive rate was 84.4% (65/77). The rate of complete pathological remission (pCR) was 39.0% (30/77). The 5-year disease free survival (DFS) was 87.3%, and 5-year overall survival (OS) was 93.6%. There was a significant difference between DFS and OS in the responsive group and non-responsive group (DFS: χ=6.762, =0.009; OS: χ=5.062, =0.024). TCH is an effective neoadjuvant therapy for patients with HER-2 positive breast cancer, and the toxic and side effects were under control.
